Improve Research Reproducibility A Bio-protocol resource
Concise Method
tooltip

Subjects

CM Carlo A. Mallio
LM Laura Messina
MP Marco Parillo
GV Gianguido Lo Vullo
BZ Bruno Beomonte Zobel
PP Paul M. Parizel
CQ Carlo C. Quattrocchi
request Request a Protocol
ask Ask a question
Favorite

We screened our in-house image database and selected a time span from January 2008 to June 2017. We identified a group of 59 consecutive patients who had undergone at least 5 intravenous GBCAs injections, each exclusively with 0.1 mmol/kg body weight of Omniscan, GE Healthcare (gadodiamide 0.5 mmol/ mL).

The exclusion criteria were: (1) empty sella; (2) previous neurosurgery; (3) abnormal renal function evaluated by calculating (Modification of Diet in Renal Disease study equation) the estimated glomerular filtration rate (GFR) from a blood sample obtained less than 3 months prior to the inclusion (GFR < 60 mL/min); (4) unsatisfactory images due to MR artifacts or absence of unenhanced sagittal T1 images; (5) presence of neoplastic lesions involving the pituitary gland.

Copyright and License information: The Author(s) ©2020
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A